bioSyntagma

Eliminating trial-and-error cancer treatments

bioSyntagma

Takara Bio USA, Inc. and bioSyntagma, Inc. Develop Method for Large-Scale Automated COVID-19 Testing

bioSyntagma, Inc, leveraged our molecular diagnostics expertise, and collaborated with Takara Bio USA, Inc., to develop and validate a new high-throughput method for detecting SARS-CoV-2 (COVID-19). The method employs automation technology and reagents from Takara BUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of the virus during this global pandemic.

Click here to learn more.

About bioSyntagma

bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.

AI Applications in Cancer Diagnostics | White Paper

Single biomarkers are no longer sufficient to describe complex biological systems such as the tumor microenvironmentor to predict response to targeted therapies. Advances in molecular analysis have led to the understanding that tumor growth is driven by a network of factors and that spatially resolved, multi-omic measurements are the key to understanding this complex network…

bioSyntagma Named Finalist for Global Sustainability Award

Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards,which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.

“We are delighted by the new sand encouraged that such an innovative group recognizes the value of creating a sustainable healthcare system,” said David Richardson, CEO of bioSyntagma. Katerva scours the globe to identify the most promising, high-impact innovations that will make the world a better place and move society closer to the 17 Sustainable Development Goals set forth by the United Nations.

Rising costs and growing numbers of diagnostic tests on the market are a huge financial burden, especially considering that most cancer patients are developing drug resistance to their treatments. “Tackling drug resistance is a crucial step in enabling personalized medicine but also in reducing costs and democratizing access,” said Colleen Ziegler, Director of Operations at bioSyntagma. “This is why we have invested so much in AI. It will change the entire landscape.” See the full list of finalists for each sustainability category at: https://katerva.net/news/10-announcing-the-finalists-of-the-2019-katerva-awards

About bioSyntagma

bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.

bioSyntagma Awarded “Best Oncology-Focused Precision Medicine Company 2018”

bioSyntagma has been awarded “Best Oncology-Focused Precision Medicine Company 2018” by Global Health and Pharma, a UK-based publication that recognizes global companies for improving public health, enhancing patient care, and lowering healthcare costs.  This award follows several commercial milestones with strategic partners and Big Pharma using bioSyntagma’s beta-instruments to offer biomarker discovery services.

Striving to eliminate-trial-and-error cancer treatments through predictive analytics and novel diagnostic tools, bioSyntagma has developed a suite of AI-enabled technologies that collectively create the Molecular Fingerprint™.  “The Molecular Fingerprint (mPrint) is how personalized medicine transitions from a buzzword to reality,” said David Richardson, CEO of bioSyntagma.  “It’s not about a specific drug but about combinations of therapies that precisely match the state of a person’s disease. We are honored GHP recognizes the impact of our work.”

The Arizona State University spin-out company and current client at the Center for Entrepreneurial Innovation is now building more instruments to support broader enrollment in their Early Access Program to provide spatial profiling services.  This will enable bioSyntagma to support data acquisition for joint discovery and predictive analytic applications.

A full list of The GHP Technology Awards 2018 winners can be accessed at https://www.ghp-news.com/technology-awards-2018.

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. Its suite of platform technologies enables comprehensive, multi-omic and spatial profiling of tissues to get a complete and informed understanding of a patient’s cancer so they can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance.  bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.